Keely Macmillan, MSPH
Advertisement
Articles by Keely Macmillan, MSPH
COVID-19 has delayed the transition to Oncology Care First, but the forthcoming model could help.
Oncology drug costs affect those entering into risk-based arrangements, and these groups must rethink their approach to evaluating risk.
Advertisement
Latest Updated Articles
Biosimilars Drive Savings in Medicare’s Oncology Care ModelPublished: June 19th 2021 | Updated:
Three Ways COVID-19 Makes the Oncology Care First Model More AttractivePublished: October 29th 2020 | Updated:
- Rethinking Downside Risk Protection Amid Growth in Precision Medicine
Published: August 16th 2020 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
CAR T-Cell Therapies, Bispecific Antibodies Usher in New Era in R/R MCL
2
Ibrutinib-Based Frontline Regimens Narrow the Survival Gap in CLL
3
Emerging Breakthroughs in Neurodegenerative Disease Treatments: Kavita Nair, PhD, FAAN
4
Global CKD Burden Nearly Doubles Since 1990, Reaching 788 Million Adults Worldwide
5
